Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia.
BACKGROUND
Therapeutic angiogenesis in ischemic myocardium has been shown to be a feasible and effective strategy to improve regional blood flow and myocardial function. However, the optimal mode of growth factor administration still needs to be established.


METHODS
Using a pig model of chronic myocardial ischemia, we evaluated the efficacy of intravenous and intracoronary infusion of FGF-2 at 2 and 6 microg/kg compared with a vehicle control. Improvement in myocardial perfusion and function was assessed by angiography, colored microspheres, and function and perfusion magnetic resonance imaging.


RESULTS
Intracoronary 6-microg/kg FGF-2 increased angiographic collaterals (p = 0.046) and increased regional blood flow to the ischemic area from 0.36 +/- 0.07 to 0.59 +/- 0.08 mL/min/g at stress (vs control, p = 0.032). Also, after 6 microg/kg intracoronary FGF-2, ejection fraction, regional wall motion, and thickening improved significantly by 9.9% +/- 1.9%, 126% +/- 39%, and 13.8% +/- 3.6%, respectively. Intravenous FGF-2 and intracoronary 2 microg/kg FGF-2 were ineffective.


CONCLUSIONS
A single 6-microg/kg intracoronary treatment with FGF-2 resulted in significant improvement in collateralization and regional and global function of chronically ischemic myocardium. Single intravenous infusion of FGF-2 was not effective in this model.
Sato
K
K
Angiogenesis Research Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Laham
R J
RJ
Pearlman
J D
JD
Novicki
D
D
Sellke
F W
FW
Simons
M
M
Post
M J
MJ
D000818:Animals; D003097:Collateral Circulation / Q000187:drug effects / Q000502:physiology; D003326:Coronary Circulation / Q000187:drug effects*; D003331:Coronary Vessels / Q000187:drug effects; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D009200:Myocardial Contraction / Q000187:drug effects; D017202:Myocardial Ischemia / Q000503:physiopathology*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D013318:Stroke Volume / Q000187:drug effects; D013552:Swine; D016896:Treatment Outcome
D016222:Fibroblast Growth Factor 2